ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
This Quarter Return
-6.48%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$5.79B
AUM Growth
+$5.79B
(-0.28%)
Cap. Flow
+$721M
Cap. Flow
% of AUM
12.45%
Top 10 Holdings %
Top 10 Hldgs %
69.76%
Holding
51
New
7
Increased
15
Reduced
5
Closed
4
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
$301M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$197M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
$45.8M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$42.9M |
| 5 |
Design Therapeutics
DSGN
|
$39.7M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$300M |
| 2 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$18.2M |
| 3 |
iTeos Therapeutics
ITOS
|
$15.6M |
| 4 |
Travere Therapeutics
TVTX
|
$13.8M |
| 5 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$9.71M |
Sector Composition
| 1 | Healthcare | 93.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $828M | 14.31% | 9,000,000 | – | – |
|
|
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $801M | 13.83% | 4,675,000 +140,000 | +3% | +$24M |
|
3
United Therapeutics
UTHR
$13.8B
| $502M | 8.67% | 3,000,000 +150,000 | +5% | +$25.1M |
|
|
XLRN
4
DELISTED
Acceleron Pharma Inc.
XLRN
| $407M | 7.03% | 3,000,000 +1,450,000 | +94% | +$197M |
|
|
5
Vertex Pharmaceuticals
VRTX
$100B
| $301M | 5.2% | +1,400,000 | New | +$301M |
|
|
ARNA
6
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $281M | 4.85% | 4,050,000 -140,000 | -3% | -$9.71M |
|
7
argenx
ARGX
$43.6B
| $255M | 4.4% | 925,500 +23,000 | +3% | +$6.33M |
|
8
Iovance Biotherapeutics
IOVA
$807M
| $253M | 4.37% | 8,000,000 +500,000 | +7% | +$15.8M |
|
9
Madrigal Pharmaceuticals
MDGL
$9.76B
| $167M | 2.88% | 1,425,000 +200,000 | +16% | +$23.4M |
|
10
Sarepta Therapeutics
SRPT
$1.78B
| $160M | 2.77% | 2,150,000 +400,000 | +23% | +$29.8M |
|
11
BioMarin Pharmaceuticals
BMRN
$11.2B
| $125M | 2.15% | 1,650,000 | – | – |
|
12
Amicus Therapeutics
FOLD
$2.34B
| $121M | 2.09% | 12,250,000 +3,250,000 | +36% | +$32.1M |
|
13
Kura Oncology
KURA
$686M
| $113M | 1.95% | 4,000,000 | – | – |
|
14
Mersana Therapeutics
MRSN
$36.5M
| $110M | 1.9% | 6,800,000 | – | – |
|
15
Adverum Biotechnologies
ADVM
$64.6M
| $78.9M | 1.36% | 8,000,000 | – | – |
|
16
PMV Pharmaceuticals
PMVP
$74.2M
| $77.6M | 1.34% | 2,360,267 +10,000 | +0.4% | +$329K |
|
|
CNST
17
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $69M | 1.19% | 2,950,000 | – | – |
|
18
Xenon Pharmaceuticals
XENE
$2.98B
| $65.3M | 1.13% | 3,650,000 +850,000 | +30% | +$15.2M |
|
19
Acadia Pharmaceuticals
ACAD
$4.38B
| $64.5M | 1.11% | 2,500,000 +550,000 | +28% | +$14.2M |
|
|
TRIL
20
DELISTED
Trillium Therapeutics Inc.
TRIL
| $61.2M | 1.06% | 5,700,000 -100,000 | -2% | -$1.07M |
|
|
21
Syndax Pharmaceuticals
SNDX
$1.41B
| $55.9M | 0.97% | 2,500,000 +2,050,000 | +456% | +$45.8M |
|
22
Relmada Therapeutics
RLMD
$37.2M
| $53.7M | 0.93% | 1,525,000 | – | – |
|
|
MRNS
23
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $50.1M | 0.86% | 3,235,000 +2,858 | +0.1% | +$44.2K |
|
24
Praxis Precision Medicines
PRAX
$958M
| $47.4M | 0.82% | 1,596,495 +51,000 | +3% | +$1.52M |
|
|
CBAY
25
DELISTED
Cymabay Therapeutics
CBAY
| $46.8M | 0.81% | 10,300,000 | – | – |
|